IGC Pharma (IGC) announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer’s disease. This strategic site directly addresses the significant impact of Alzheimer’s in the region.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma presents genetic toxicology safety data on IGC-AD1
- IGC Pharma announces strategic investment from advisors
- IGC Pharma expands CALMA trial with addition of Butler Hospital Program
- IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health
- IGC Pharma expands CALMA clinical trial